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Ang-(1–7) is produced via degradation of Ang II by the human angiotensin converting enzyme, also known as ACE2. In the
cardiovascular system, Ang-(1–7) has been shown to produce eﬀects that are opposite to those of Ang II. These include smooth
muscle relaxation and cardioprotection. While the roles of Ang-(1–7) in other systems are currently topic of intense research,
functional data suggest a relaxation action in gastrointestinal smooth muscles in a way that corroborates the results obtained from
vascular tissues. However, more studies are necessary to determine a relevant role for Ang-(1–7) in the gastrointestinal system.
The Ang-(1–7) actions are mediated by a distinct, functional, Ang-(1–7) receptor: the Mas receptor as shown by diverse studies
involving site-speciﬁc binding techniques, selective antagonists, and targeted gene deletion. This paper provides an overview of the
functional role and the molecular pathways involved in the biosynthesis and activity of Ang-(1–7) in diverse systems.
1. A Brief Historical Overview
Until the late 80s, it was thought that most of the biologi-
cal activity of angiotensin peptides was based on their inter-
action with the AT1 receptor at the C-terminal side chain
of a phenylalanine residue in the position 8 (Phe8)[ 1, 2].
Consequently, it was assumed that fragments of Ang II
lacking the C-terminal Phe8 were biologically inactive [3]. A
number of studies have shown that the N-terminal hep-
tapeptideangiotensin-(1–7)[Ang-(1–7)],alsonamedasdes-
[Phe8]-angiotensin II [4], lacked vasopressor eﬀect [5, 6], al-
dosterone release activity [5], and central dipsogenic action
[7].
However, in 1988, Santos and coworkers showed that
Ang-(1–7)wasproducedasthemainmetaboliteofangioten-
sin I (Ang I) in dog brainstem and spinal cord, which is
produced even in the presence of angiotensin-converting
enzyme (ACE) inhibitors, suggesting an ACE-independent
route [8]. Further studies have shown that Ang-(1–7) stimu-
lates arginine vasopressine (AVP) release from the rat hy-
pothalamo-neurohypophysial system (HNS) with potency
comparable to angiotensin II (Ang II) [9]. These ﬁndings
triggered general scientiﬁc interest in the area with a series
of studies involving site-speciﬁc, functional antagonism, and
targeted-gene deletion that, among other techniques, have
resultedintheidentiﬁcationofACE2andoftheMas receptor
as the main agents responsible for the biosynthesis and
actions of Ang-(1–7) at the molecular level.
This paper provides an overview of the molecular
pathways involved in the biosynthesis and activity of Ang-
(1–7) in the vascular and gastrointestinal systems with
emphasis on their smooth muscle structures, and the lim-
ited availability of such information in the gastrointestinal
tract.2 International Journal of Hypertension
2. Biosynthesis andDegradation of Ang-(1–7)
ACE2 is the enzyme responsible for the biosynthesis of Ang-
(1–7). ACE2 is a membrane-associated zinc metalloprotease
and a homologue of the human ACE isoforms, which is
highly expressed in several tissues such as human heart,
kidney, lungs, and testis [10, 11]. There is also evidence
for the presence of ACE2 in smooth muscles: in the
cardiovascular system, studies have shown the expression of
ACE2 in the media of thoracic aorta and common carotid
arteries from spontaneously hypertensive rats (SHRs) [12].
In line with these studies, ACE2 has also been shown to be
expressed in vascular smooth muscle cells (VSMCs) isolated
from rat aorta [13, 14], and in renal and mesenteric arteries
from spontaneously hypertensive stroke-prone rats (SHRSP)
[15]. In the gastrointestinal system, studies suggest a role for
local biosynthesis of Ang-(1–7). These include an inhibitory
eﬀect in the basal tone of the internal anal sphincter [16]
and the identiﬁcation of ACE2 mRNA in the stomach wall
of rats [17]. In addition, studies using quantitative real-
time polymerase chain reaction (QRT-PCR) have made the
novel observation that ACE 2 shows levels of expression in
the gastrointestinal system that are comparable to those in
the cardiovascular system. Particularly high levels of ACE2
have been found in duodenum, jejunum, ileum, caecum,
and colon. Therefore, consideration should also be given
to a potential role for ACE2 in gastrointestinal physiology
and pathophysiology [18]. However, other than this, there is
relatively scarce information about formation and actions of
Ang-(1–7) in the gastrointestinal system.
Despite its homology with ACE, ACE2 is functionally
diﬀerent as it acts as a C-terminal carboxypeptidase rather
than a C-terminal dipeptidase by cleaving the C-terminal of
a residue of Leu in the structure of Ang I or a residue of Phe
in Ang II. This activity, respectively, generates angiotensin-
(1–9) [Ang-(1–9)] [10, 11] or Ang-(1–7) [11, 19].
There are also pharmacological diﬀerences between ACE
and ACE2. ACE2 is insensitive to classic ACE inhibitors such
as lisinopril [10, 11], enalaprilat, or captopril [11]a sw e l l
as other ACE inhibitors [20]. The diﬀerential sensitivity to
ACE inhibitors results from amino acid substitutions in the
substrate binding site from ACE2. Studies show that ACE2
has an Arginine (Arg) residue in the position 273 instead
of the Glutamine (Gln) residue normally found in ACE
[21]. This substitution allosterically impairs the interaction
between ACE2 and classic ACE inhibitors because of the
larger size of Arg273, which limits the size of the S2
  substrate
subsite in ACE2 [21].
As mentioned above, ACE2 catalyzes the conversion of
both Ang I and Ang II into smaller fragments. Donoghue
et al. [10] ﬁrst showed that ACE2 is able to hydrolyze Ang
I. Following this, Vickers et al. [19] showed that ACE2 more
eﬃciently hydrolyzes Ang II than Ang I since the latter is
only partially hydrolyzed. ACE2 and the resulting formation
of Ang-(1–7) play an important role in the cardiovascular
system. Studies by Igase et al. [12] have shown that blockade
of AT1 receptors in the media layer of thoracic aortas isolated
from SHR resulted in signiﬁcant increases in the expression
of ACE2 at the mRNA and protein levels. This eﬀect was
consistently associated with increased levels of Ang-(1–7),
suggesting that ACE2 generates Ang-(1–7) locally. Corrob-
orating these results, studies by Lavrentyev and Malik [14]
have found that reduction in ACE2 expression is followed by
a reduction in the cellular levels of Ang-(1–7) in rat aorta
VSMC. Together, these studies suggest the involvement of
ACE2 in the generation of Ang-(1–7) within the VSMC.
Similar results have been found in human coronary vessels
[22]a n dr a ts t o m a c hw a l l[ 17].
In addition to ACE2, there are other enzymes that have
been reported to release Ang-(1–7). Endopeptidases are the
ﬁrst example and have been implicated in the biosynthesis
of Ang-(1–7) mainly from Ang I. As an example, prolyl
endopeptidase converts Ang I into Ang-(1–7) as shown in
NG108-15 neuroblastoma versus glioma hybrid cells [23]
and in endothelial cells from human and bovine aorta
as well as in umbilical veins [24]. As another example,
neutral endopeptidase (NEP or neprilysin) accounts for the
generationofmostofthecirculatingAng-(1–7)derivedfrom
AngIassuggestedbystudiesinSHRandWistar-Kyoto(WK)
rats [25]. In addition, thimet oligopeptidase (EC 3.4.24.15)
forms Ang-(1–7) from Ang I in VSMC [26]. The catalytic
action of these peptidases is responsible for the eﬃciency of
theAngI-dependentpathwaysinthebiosynthesisofAng-(1–
7)becauseACE2hydrolyzesAngIIratherthanAngI[19,20].
ACE has also been reported to be able to release Ang-(1–
7). Even though it does not catalyze the generation of Ang-
(1–7) from Ang I or Ang II, ACE is able to cleave Ang-(1–9)
leading to the generation of Ang-(1–7) [20]. Furthermore,
ACE is an important component in the catabolism of Ang-
(1–7).
The ﬁrst evidence that pointed a potential role for ACE
in the degradation of Ang-(1–7) came from the ﬁndings
obtained by Kohara et al. [27]. In this study, the authors
observed that the chronic treatment of SHR or WK rats with
the ACE inhibitors ceranopril or lisinopril augmented the
circulating levels of Ang-(1–7). Corroborating with Kohara
et al. [27], Luque et al. [28] showed that the chronic therapy
of essential hypertensive subjects with captopril reduced the
diastolic blood pressure without changing the plasma levels
of Ang II while increasing the levels of Ang-(1–7). Taken
together, these ﬁndings suggest a potential role for ACE in
the degradation of Ang-(1–7), which may be involved in the
antihypertensive eﬀects from ACE inhibitors.
Indeed, in vitro experiments obtained by Chappell et al.
[29]showedthatACEcleavestheIsoleucine(Ile)5-His6 bond
of Ang-(1–7) with a high speciﬁcity constant. The hydrolysis
of Ang-(1–7) catalyzed by ACE involves the N-domain of the
enzyme [30] and leads to the formation of angiotensin-(1–5)
[Ang-(1–5)] [29].
3. Effects Elicitedby Ang-(1–7)
Studies show that Ang-(1–7) has a cardioprotective role
mainly attributable to counteraction of the Ang II eﬀects,
which contribute to maintaining the vascular homeostasis
and attenuating the progression of atherogenesis [31, 32]
among other eﬀects as further explained below.International Journal of Hypertension 3
Campagnole-Santos et al. [33] were the ﬁrst to demon-
strate the vascular eﬀects induced by Ang-(1–7). The authors
observed that the injection of Ang-(1–7) in the rat dorsal
motor nucleus of the vagus elicited a centrally mediated
hypotension similar to that induced by Ang II. Later, the
authors showed that intracerebroventricular injections of
Ang-(1–7) increased the baroreﬂex sensitivity for the control
of the heart rate in conscious rats, suggesting that Ang-
(1–7) facilitates the baroreﬂex by inducing depressor eﬀects
into the dorsal medulla [34]. In this context, Benter et al.
[35] found that systemic injections of Ang-(1–7) transiently
reduced the systolic pressure in SHR, suggesting a potential
counterregulatory eﬀect of Ang-(1–7) on the pressor eﬀects
elicited by the main agents that increase the total peripheral
resistanceduringhypertension,likeAngIIandα1-adrenergic
agonists. Later, the authors conﬁrmed their hypothesis [36]
by showing that the intravenous administration of Ang-(1–
7) reduced the pressor responsiveness to the α1-adrenergic
agonist phenylephrine, and to Ang II, and improved the
sensitivityofthereﬂexcontroloftheheartrateinSHR.These
results were suggestive that Ang-(1–7) activated antihyper-
tensive mechanisms.
Additional studies showed that Ang-(1–7) was responsi-
bleforthehypotensiveeﬀectsofACEinhibitorslikelisinopril
and losartan. Experiments using monoclonal antibodies
selective for Ang-(1–7) showed that the antihypertensive
eﬀects of lisinopril and losartan were reversed by scavenging
the circulating Ang-(1–7) in SHR [29, 30, 37, 38]. Following
diverse studies showed that Ang-(1–7) has a relaxation eﬀect
of its own. Meng et al. showed that Ang-(1–7) caused a mild
dilatationofcerebralarteriolesviaamechanismthatinvolves
the release of cyclooxygenases (COX) metabolites [39].
P¨ orsti et al. [40] demonstrated that Ang-(1–7) induced an
endothelium- and nitric oxide synthase (NOS) metabolites-
mediated relaxation in porcine coronary arteries. Similar
ﬁndings were obtained by Brosnihan et al. [41], who
showed an endothelium- and NOS metabolites-mediated
relaxation evoked by Ang-(1–7) in canine coronary artery.
Comparable results were found in other animal species using
a number of tissues suggesting that Ang-(1–7) has a wide-
spread relaxation eﬀect in the cardiovascular system via NO
release[42–44].Inthevascularsystem,thecounterregulatory
actions of Ang-(1–7) over the eﬀects produced by Ang
II occur at the molecular level. Sampaio et al. [45]h a v e
shown that Ang-(1–7) inhibits the assembly and activation
of NAD(P)H oxidase induced by Ang II by inhibiting Ang
II-induced phosphorylation of p47phox, which is crucial
to the NAD(P)H oxidase activation. This Ang II-mediated
mechanism results in O2
− generation [46], NO inactivation
[47], and has been correlated with diabetes. During diabetes
mellitus, the vascular endothelium is an important source
of NAD(P)H oxidase-derived O2
−, which is involved in
the reduction of endothelial NO availability and in the
consequent endothelial dysfunction [47, 48]. Therefore, the
counteractive eﬀects by Ang-(1–7) over Ang II make it a
potentially important therapeutic target to attenuate the
endothelial dysfunction and in treating diabetes mellitus.
Ang-(1–7) also has antiproliferative eﬀects in the cardio-
vascularsystem.Freemanetal.[49]haveshownthatAng-(1–
7) inhibits incorporation of mitogen-stimulated thymidine
in rat aortic VSMC thus inhibiting cellular growth. The
mechanism was characterized by Tallant and Clark [50],
whoshowedthatAng-(1–7)attenuatesthemitogenicactivity
of MAPK by a cAMP-dependent protein kinase (PKA),
which is activated after a PGI2-mediated increase in cAMP
production. In addition, Strawn et al. [51] have shown that
Ang-(1–7) treatment reduced the DNA synthesis and the
cross-sectionalareaofneointima inratcarotidarteryinjured
by balloon catheter. In line with these results, Langeveld
et al. [52] observed that Ang-(1–7) treatment reduces the
neointimal thickness in rat abdominal aorta after stent
implantation and restores the impaired endothelial function.
Many other studies also support the concept that Ang-(1–7)
playsanimportantroleinneointimalre-endothelizationand
inhibition of neointimal formation and restenosis [52–54].
Studies also provide evidence for a role for Ang-(1–7) in
reducing thrombus formations. Experiments in rat vena cava
have shown that Ang-(1–7) reduces the thrombus weight
and platelet adhesion to ﬁbrilar collagen by a mechanism
involving NOS and COX metabolites [55]. In addition,
Tesanovic et al. [56] found that the chronic treatment
with Ang-(1–7) reduced the development of atherosclerotic
lesion in ApoE (−/−) and high-fat diet-fed mice, followed
by an increase in the local expression of eNOS. These
ﬁndings have opened new perspectives on the promising
vasculo-andatheroprotectiveeﬀectsofAng-(1–7)suggesting
therapeutic potentials for the atherosclerosis, thrombosis,
and atherothrombosis.
4.Mas Receptor
The Mas receptor was ﬁrst cloned and sequenced by Young
et al. [57] in cotransfected NIH 3T3 cells from nude mice
and revealed a very hydrophobic protein, containing seven
potential transmembrane domains.
A connection between the Mas receptor and Ang-(1–
7) was ﬁrst established by Santos et al. [58]. Using binding
studies performed in kidney sections from wild-type and
Mas-deﬁcient mice, the authors demonstrated that Ang-(1–
7) binding was absent in kidneys from Mas-deﬁcient mice,
but preserved in wild-type membranes. In addition, the
authors also showed that Ang-(1–7) binding was preserved
in membranes isolated from AT1-o rA T 2-deﬁcient animals,
suggesting a twofold conclusion: (1) that Ang-(1–7) has
limited interactions with AT1 and AT2 receptors and (2)
that it mainly binds to Mas receptors [58]. These results
were conﬁrmed by further studies showing high aﬃnity sites
for Ang-(1–7) in Mas receptors. The results also showed
that the Mas receptor has very low aﬃnity for AT1 or
AT2 ligands, excluding the hypothesis that Ang-(1–7) would
directly interact with AT1 or AT2 receptors [58].
The ﬁrst evidence for a functional role for the Mas
receptor as the mediator of the Ang-(1–7) eﬀects in the
vascular system was also provided by Santos et al. [58].
The authors showed that the relaxation induced by Ang-
(1–7) in mouse aorta was absent in Mas-deﬁcient mice.4 International Journal of Hypertension
The authors were also the ﬁrst group to develop a selective
antagonist for the Mas receptor called D-Ala7-Ang-(1–7)
also known as A-779 [58, 59]. These ﬁndings fostered
publication of many functional studies supporting a role for
Mas receptors in the eﬀects induced by Ang-(1–7). These
include indirect (centrally mediated) antihypertensive eﬀects
[60]a n dl o c a le ﬀects at the cellular [61] and molecular [44]
levels. Tirapelli et al. [61] have shown that A-779 inhibited
vasorelaxant eﬀects caused by Ang-(1–7) in rat carotid artery
in a concentration-dependent fashion. Sampaio et al. [44]
demonstrated that A-779 blocks the phosphorylation of
eNOS induced by Ang-(1–7) in human aortic endothelial
cells, suggesting the involvement of Mas receptors in this
eﬀect. A-779 also blocked the inhibitory eﬀect of Ang-(1–
7) on VSMC growth, suggesting the participation of Mas
receptors in the antiproliferative action of Ang-(1–7) [62].
There is also functional evidence directly supporting
ar o l ef o rMas receptors in the antithrombotic eﬀect of
Ang-(1–7). A-779 dose-dependently inhibits the Ang-(1–
7)-induced reduction in venous thrombus weight [55]. In
addition, A-779 reduces the development of atherosclerotic
lesion by Ang-(1–7) in mice. Interestingly, this eﬀect was
more evident when A-779 was combined with the AT2-
antagonists, suggesting an important interaction between
Mas and AT2 receptors in mediating the atheroprotective
eﬀect of Ang-(1–7) [56].
Multipronged studies also show a potential role for Mas
receptors and Ang-(1–7) in the regulation of gastrointestinal
smooth muscle motility. Studies by De Godoy et al. in Dr.
Rattan’s laboratory [16] have shown that Ang-(1–7) dose-
dependently reduces the basal tone of spontaneously con-
tracted internal anal sphincter of rats. The studies also show
that this relaxation eﬀect is abolished by A-779. In addition,
the studies have shown that A-779 had no signiﬁcant eﬀect
on the contractile response of Ang II [16]. Whether Ang-
(1–7) has an important role in the gastrointestinal system
remains to be determined.
Inclosing,Ang-(1–7)relaxessmoothmusclesviainterac-
tions with the Mas receptor that elicit well-known molecular
mechanisms of relaxation such as the release of NO. Limited
studies suggest a potential role for Ang-(1–7) in regulating
motility of gastrointestinal smooth muscles, but additional
studies are necessary to further determine Ang-(1–7) actions
and therapeutic potentials in the gastrointestinal system. On
the other hand, the eﬀectsof Ang-(1–7) in the cardiovascular
systemarebetterunderstoodandprovidestrongevidencefor
the cardiovascular protective action that can be selectively
modulated via Mas ligands and have important therapeutic
implications for human therapy.
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